Aspirin to Prevent Stroke in Nonrheumatic Atrial Fibrillation
To the Editor: The value of aspirin for the prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation has been endorsed in two large, placebo-controlled, randomized, double-blind clinical trials. Using intention-to-treat analysis, one reported a 42 percent reduction in ischemic...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1992-07, Vol.327 (4), p.286-286 |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 286 |
|---|---|
| container_issue | 4 |
| container_start_page | 286 |
| container_title | The New England journal of medicine |
| container_volume | 327 |
| description | To the Editor:
The value of aspirin for the prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation has been endorsed in two large, placebo-controlled, randomized, double-blind clinical trials. Using intention-to-treat analysis, one reported a 42 percent reduction in ischemic strokes
1
and the other a 16 percent reduction.
2
Pooled analysis showed an overall reduction of 35 percent.
3
Despite these findings some have continued to express doubts about the efficacy of aspirin.
4
When the Stroke Prevention in Atrial Fibrillation (SPAF) study was notified by the independent safety and monitoring committee that the placebo arm of our trial should be terminated, . . . |
| doi_str_mv | 10.1056/NEJM199207233270419 |
| format | Article |
| fullrecord | <record><control><sourceid>mms_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1056_NEJM199207233270419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NJ199207233270419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c283t-9820f4afe4786c9079b999a626c4d503e9ed35f35c425d4007363ae4fc72f21d3</originalsourceid><addsrcrecordid>eNp9kE1LxDAYhIMoWFd_gZfcpfomb5o0Bw9l2fWDdRXUc8mmCWbtx5JUwX9vZT2Kcxl4mJnDEHLO4JJBIa_Wi_sHpjUHxRG5AsH0AclYgZgLAfKQZAC8zIXSeExOUtrCJCZ0Rq6rtAsx9HQc6FN0n64f6fMYh3dHJ7ge-vjmPjozBkurMQbT0mXYxNC2Exr6U3LkTZvc2a_PyOty8TK_zVePN3fzapVbXuKY65KDF8Y7oUppNSi90VobyaUVTQHotGuw8FhYwYtGACiUaJzwVnHPWYMzgvtdG4eUovP1LobOxK-aQf3zQP3HA1PrYt_qulT3btv9m_4GkfhZ4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Aspirin to Prevent Stroke in Nonrheumatic Atrial Fibrillation</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><description>To the Editor:
The value of aspirin for the prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation has been endorsed in two large, placebo-controlled, randomized, double-blind clinical trials. Using intention-to-treat analysis, one reported a 42 percent reduction in ischemic strokes
1
and the other a 16 percent reduction.
2
Pooled analysis showed an overall reduction of 35 percent.
3
Despite these findings some have continued to express doubts about the efficacy of aspirin.
4
When the Stroke Prevention in Atrial Fibrillation (SPAF) study was notified by the independent safety and monitoring committee that the placebo arm of our trial should be terminated, . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199207233270419</identifier><language>eng</language><publisher>Massachusetts Medical Society</publisher><ispartof>The New England journal of medicine, 1992-07, Vol.327 (4), p.286-286</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c283t-9820f4afe4786c9079b999a626c4d503e9ed35f35c425d4007363ae4fc72f21d3</citedby><cites>FETCH-LOGICAL-c283t-9820f4afe4786c9079b999a626c4d503e9ed35f35c425d4007363ae4fc72f21d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199207233270419$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199207233270419$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,778,782,2748,2749,26086,27907,27908,52365,54047</link.rule.ids></links><search><title>Aspirin to Prevent Stroke in Nonrheumatic Atrial Fibrillation</title><title>The New England journal of medicine</title><description>To the Editor:
The value of aspirin for the prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation has been endorsed in two large, placebo-controlled, randomized, double-blind clinical trials. Using intention-to-treat analysis, one reported a 42 percent reduction in ischemic strokes
1
and the other a 16 percent reduction.
2
Pooled analysis showed an overall reduction of 35 percent.
3
Despite these findings some have continued to express doubts about the efficacy of aspirin.
4
When the Stroke Prevention in Atrial Fibrillation (SPAF) study was notified by the independent safety and monitoring committee that the placebo arm of our trial should be terminated, . . .</description><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAYhIMoWFd_gZfcpfomb5o0Bw9l2fWDdRXUc8mmCWbtx5JUwX9vZT2Kcxl4mJnDEHLO4JJBIa_Wi_sHpjUHxRG5AsH0AclYgZgLAfKQZAC8zIXSeExOUtrCJCZ0Rq6rtAsx9HQc6FN0n64f6fMYh3dHJ7ge-vjmPjozBkurMQbT0mXYxNC2Exr6U3LkTZvc2a_PyOty8TK_zVePN3fzapVbXuKY65KDF8Y7oUppNSi90VobyaUVTQHotGuw8FhYwYtGACiUaJzwVnHPWYMzgvtdG4eUovP1LobOxK-aQf3zQP3HA1PrYt_qulT3btv9m_4GkfhZ4Q</recordid><startdate>19920723</startdate><enddate>19920723</enddate><general>Massachusetts Medical Society</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920723</creationdate><title>Aspirin to Prevent Stroke in Nonrheumatic Atrial Fibrillation</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c283t-9820f4afe4786c9079b999a626c4d503e9ed35f35c425d4007363ae4fc72f21d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><collection>CrossRef</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aspirin to Prevent Stroke in Nonrheumatic Atrial Fibrillation</atitle><jtitle>The New England journal of medicine</jtitle><date>1992-07-23</date><risdate>1992</risdate><volume>327</volume><issue>4</issue><spage>286</spage><epage>286</epage><pages>286-286</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
The value of aspirin for the prevention of ischemic stroke in patients with nonrheumatic atrial fibrillation has been endorsed in two large, placebo-controlled, randomized, double-blind clinical trials. Using intention-to-treat analysis, one reported a 42 percent reduction in ischemic strokes
1
and the other a 16 percent reduction.
2
Pooled analysis showed an overall reduction of 35 percent.
3
Despite these findings some have continued to express doubts about the efficacy of aspirin.
4
When the Stroke Prevention in Atrial Fibrillation (SPAF) study was notified by the independent safety and monitoring committee that the placebo arm of our trial should be terminated, . . .</abstract><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJM199207233270419</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1992-07, Vol.327 (4), p.286-286 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_crossref_primary_10_1056_NEJM199207233270419 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| title | Aspirin to Prevent Stroke in Nonrheumatic Atrial Fibrillation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-mms_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aspirin%20to%20Prevent%20Stroke%20in%20Nonrheumatic%20Atrial%20Fibrillation&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.date=1992-07-23&rft.volume=327&rft.issue=4&rft.spage=286&rft.epage=286&rft.pages=286-286&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM199207233270419&rft_dat=%3Cmms_cross%3ENJ199207233270419%3C/mms_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |